Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure

Conditions

• Heart Failure

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Optimized version of the EPIC-HF Checklist — BEHAVIORAL
  The EPIC-HF checklist is a 1-page patient activation tool that contains approved and guideline-recommended medications and target doses for HFrEF. The EPIC-HF checklist allows patients to see recommended doses and categories of GDMT, which they can compare to their current medications and dosing. The EPIC-HF checklist has been refined and updated to include GDMT prescription and has been optimized for delivery through electronic medical record (EMR) systems. The checklist is being used as a patient activation/ discussion tool only and data entered on the checklist will not be collected for purposes of this study.
• Clinician-facing Decision Support — BEHAVIORAL
  Information regarding GDMT (including target doses and medications) analogous to what is contained in the checklist will be provided to clinicians in intervention clinics. This information will be visible at the time of the encounter.
• Standard of Care — BEHAVIORAL
  Patients of clinics that are not implementing EPIC-HF checklist will not have the checklist available to them through the electronic medical record (EMR).

Study Details

Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF). However, studies have shown that these medications, known together as guideline-directed medical therapy (GDMT), are not being used in clinical practice less often than they could be. Several tools to promote broader use of these treatments (including patient checklists) have shown promise for increasing use of GDMT. However, these tools have not been broadly implemented within large health systems. The goal of this study is to see if using these tools broadly within cardiology clinics will increase the use of GDMT. This study is important because it could help improve the use of GDMT, which may lead to improved patient care and outcomes.

Key Dates

Start date

Mar 24, 2025

Status verified

Apr 2026

Primary completion

Jun 30, 2026

Completion

Jun 30, 2026

Study Design

Enrollment

4,000 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Arms

• Other: Optimized version of the EPIC-HF Checklist
  Patients of clinics that are randomized to implement the checklist will be sent the checklist in advance of their visit via their electronic medical record (EMR) portal.
• Other: EPIC-HF Checklist for Patients and Clinician-facing Decision Support
  Patients of clinics that are randomized to implement the checklist will be sent the checklist in advance of their visit via their electronic medical record (EMR) portal. During this period of the study, clinicians in intervention clinics will also have access to analogous decision-support via EMR.
• Active Comparator: Standard of Care
  Patients of clinics that are randomized to the standard of care will not have the EPIC-HF checklist available for viewing in their electronic medical record (EMR).

Primary Outcome Measure

Number of Participants with GDMT Initiation or Intensification [ Time Frame: 30 Days after Clinic Visit ]

Central Contacts

• Neal W Dickert, MD, PhD
  404-712-6834
  [email protected]

Locations (4)

Find similar trials in Atlanta, GA

Related Studies

• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  Recruiting · Medtronic · Birmingham, Alabama
• The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
  Recruiting · Cardiac Dimensions, Inc. · Gilbert, Arizona
• Assessment of CCM in HF With Higher Ejection Fraction
  Recruiting · Impulse Dynamics · Birmingham, Alabama
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
  PHASE3 · Recruiting · Novo Nordisk A/S · Alexander City, Alabama